

Kazue Yoneda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1025266/publications.pdf>

Version: 2024-02-01

67
papers

1,901
citations

394286

19
h-index

265120

42
g-index

70
all docs

70
docs citations

70
times ranked

2985
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating Tumor Cell as a Diagnostic Marker in Primary Lung Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 6980-6986.	3.2	296
2	Prognostic Impact of Circulating Tumor Cells in Patients with Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 512-519.	0.5	166
3	Hepatocyte Nuclear Factor-4 α Is Essential for Glucose-stimulated Insulin Secretion by Pancreatic β -Cells. <i>Journal of Biological Chemistry</i> , 2006, 281, 5246-5257.	1.6	148
4	The HNF-1 target Collectrin controls insulin exocytosis by SNARE complex formation. <i>Cell Metabolism</i> , 2005, 2, 373-384.	7.2	141
5	Podoplanin: An emerging cancer biomarker and therapeutic target. <i>Cancer Science</i> , 2018, 109, 1292-1299.	1.7	134
6	Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer. <i>British Journal of Cancer</i> , 2019, 121, 490-496.	2.9	100
7	Significant increase in circulating tumour cells in pulmonary venous blood during surgical manipulation in patients with primary lung cancer. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2014, 18, 775-783.	0.5	95
8	Circulating Tumor Cells in Pulmonary Venous Blood of Primary Lung Cancer Patients. <i>Annals of Thoracic Surgery</i> , 2009, 87, 1669-1675.	0.7	94
9	Treatment of Non-small Cell Lung Cancer with β -EGFR γ -mutations. <i>Journal of UOEH</i> , 2019, 41, 153-163.	0.3	65
10	Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer. <i>Immunology Letters</i> , 2018, 196, 155-160.	1.1	55
11	EpCAM-independent capture of circulating tumor cells with a "universal CTC-chip"™. <i>Oncology Reports</i> , 2017, 37, 77-82.	1.2	46
12	Prognostic factors of advanced or postoperative recurrent non-small cell lung cancer targeted with immune check point inhibitors. <i>Journal of Thoracic Disease</i> , 2019, 11, 1117-1123.	0.6	46
13	Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC). <i>Journal of UOEH</i> , 2018, 40, 173-189.	0.3	45
14	Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC). <i>Surgery Today</i> , 2016, 46, 25-37.	0.7	30
15	Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 382-392.e1.	0.4	28
16	Positive correlation between postoperative tumor recurrence and changes in circulating tumor cell counts in pulmonary venous blood (pvCTC) during surgical manipulation in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 298-306.	0.6	28
17	Circulating tumor cells (CTCs) in lung cancer: current status and future perspectives. <i>Lung Cancer: Targets and Therapy</i> , 2010, 1, 77.	1.3	27
18	Prognostic impact of PD-L1 expression in correlation with neutrophil-to-lymphocyte ratio in squamous cell carcinoma of the lung. <i>Scientific Reports</i> , 2020, 10, 1243.	1.6	23

#	ARTICLE	IF	CITATIONS
19	Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM). <i>Annals of Surgical Oncology</i> , 2014, 21, 472-480.	0.7	21
20	Detection of circulating tumor cells with a novel microfluidic system in malignant pleural mesothelioma. <i>Cancer Science</i> , 2019, 110, 726-733.	1.7	20
21	Perioperative pirfenidone treatment for lung cancer patients with idiopathic pulmonary fibrosis. <i>Surgery Today</i> , 2020, 50, 469-474.	0.7	20
22	Detection of Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM) with the Universal-CTC-Chip and An Anti-Podoplanin Antibody NZ-1.2. <i>Cells</i> , 2020, 9, 888.	1.8	19
23	Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung. <i>Journal of Surgical Oncology</i> , 2018, 117, 1563-1569.	0.8	18
24	Frequency of epidermal growth factor receptor mutations in Bangladeshi patients with adenocarcinoma of the lung. <i>International Journal of Clinical Oncology</i> , 2014, 19, 45-49.	1.0	17
25	Squamous cell carcinoma transformation from adenocarcinoma as an acquired resistance after the EGFR TKI therapy in (EGFR-mutated) non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, E526-E531.	0.6	16
26	Complete resection of the primary lesion improves survival of certain patients with stage IV non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 5278-5287.	0.6	15
27	Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy. <i>International Journal of Clinical Oncology</i> , 2012, 17, 33-39.	1.0	14
28	Predictive factors of postoperative survival among patients with pulmonary neuroendocrine tumor. <i>Journal of Thoracic Disease</i> , 2018, 10, 6912-6920.	0.6	13
29	Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer. <i>Cancer Letters</i> , 2021, 522, 119-128.	3.2	13
30	HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features. <i>Npj Precision Oncology</i> , 2022, 6, 5.	2.3	13
31	Diagnosis of synchronous primary lung adenocarcinomas based on epidermal growth factor (EGFR) gene status: A case report. <i>Lung Cancer</i> , 2010, 68, 498-500.	0.9	12
32	A liquid biopsy in primary lung cancer. <i>Surgery Today</i> , 2019, 49, 1-14.	0.7	12
33	Capture of mesothelioma cells with Universal-CTC-chip. <i>Oncology Letters</i> , 2017, 15, 2635-2640.	0.8	11
34	The clinical value of circulating tumour cells (CTCs) in patients undergoing pulmonary metastasectomy for metastatic colorectal cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 1569-1577.	0.6	11
35	Circulating Endothelial Cell (CEC) as a Diagnostic and Prognostic Marker in Malignant Pleural Mesothelioma (MPM). <i>Annals of Surgical Oncology</i> , 2012, 19, 4229-4237.	0.7	10
36	Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung. <i>Surgical Case Reports</i> , 2018, 4, 19.	0.2	10

#	ARTICLE	IF	CITATIONS
37	Difficulty of treatment for pleural epithelioid hemangioendothelioma: a report of a case. <i>General Thoracic and Cardiovascular Surgery</i> , 2020, 68, 190-193.	0.4	10
38	CD155 expression and its clinical significance in non-small cell lung cancer. <i>Oncology Letters</i> , 2022, 23, 166.	0.8	7
39	Abstract 380: Capture of EpCAM-negative circulating tumor cells (CTCs) with a "Universal CTC-Chip". <i>Cancer Research</i> , 2015, 75, 380-380.	0.4	6
40	Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report. <i>Case Reports in Oncology</i> , 2017, 9, 565-567.	0.3	5
41	Classification of Circulating Tumor Cells in Fluorescence Microscopy Images Based on SqueezeNet. , 2019, , .		5
42	Detection of Circulating Tumor Cells in Fluorescence Microscopy Images Based on ANN Classifier. <i>Mobile Networks and Applications</i> , 2020, 25, 1042-1051.	2.2	5
43	Prognostic impact of circulating tumor cells detected with the microfluidic "universal CTC-chip" for primary lung cancer. <i>Cancer Science</i> , 2022, 113, 1028-1037.	1.7	5
44	Novel circulating tumor cell detection chip combining conventional podoplanin and EGFR antibodies for all histological malignant pleural mesothelioma. <i>Oncology Letters</i> , 2021, 22, 522.	0.8	4
45	Circulating Tumor Cells as an Indicator of Postoperative Lung Cancer: A Case Report. <i>American Journal of Case Reports</i> , 2016, 17, 663-665.	0.3	2
46	Circulating tumor cells: A novel detection system with "universal" CTC-chip. , 2016, , .		2
47	Outcomes of patients undergoing surgery for thymic carcinoma: a single-center experience. <i>Journal of Thoracic Disease</i> , 2018, 10, 4283-4286.	0.6	2
48	Combination efficacy of mTOR and MEK inhibitor in malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2013, 31, e18557-e18557.	0.8	2
49	Automatic Identification of CTC in Fluorescence Microscope Images Using Segmentation Algorithm of Cell Nucleus. , 2021, , .		2
50	Gene Mutation Analysis in Determining Late Recurrence of Adenocarcinoma of the Lung. <i>Annals of Thoracic Surgery</i> , 2015, 100, 711-713.	0.7	1
51	Automatic segmentation of cell candidate regions in microscopy images based on an optimization algorithm. , 2016, , .		1
52	Circulating Tumor Cell Count Can Be a Useful Prognostic Factor in Lung Resection via Cardiopulmonary Bypass. <i>Case Reports in Oncology</i> , 2017, 10, 169-174.	0.3	1
53	Automatic identification of circulating tumor cells in fluorescence microscopy images based on AdaBoost. , 2017, , .		1
54	Automatic Identification of Circulating Tumor Cells in Fluorescence Microscopy Images Based on ANN. , 2017, , .		1

#	ARTICLE	IF	CITATIONS
55	Mediastinal Tracheostoma for Treatment of Tracheostenosis after Tracheostomy in a Patient with Mucopolysaccharidosis-Induced Tracheomalacia. Case Reports in Surgery, 2017, 2017, 1-4.	0.2	1
56	Automatic Detection of Cell Regions in Microscope Images Based on BFED Algorithm. , 2018, , .		1
57	Fenestration without rib resection for postoperative bronchopleural fistula. Surgical Case Reports, 2019, 5, 70.	0.2	1
58	Salvage surgery combined with descending aorta resection for lung cancer. Surgical Case Reports, 2019, 5, 114.	0.2	1
59	Return to work after surgical treatment for malignant pleural mesothelioma: report of a case. General Thoracic and Cardiovascular Surgery, 2019, 67, 897-900.	0.4	1
60	Circulating tumor cells. , 2014, , .		0
61	Molecular Diagnosis and Targeting for Lung Cancer. Current Human Cell Research and Applications, 2018, , 1-32.	0.1	0
62	Recent topics of lung neuroendocrine tumors. Journal of Thoracic Disease, 2019, 11, E133-E134.	0.6	0
63	The impact of perioperative heparin bridging therapy in lung cancer surgery. General Thoracic and Cardiovascular Surgery, 2020, 68, 623-628.	0.4	0
64	Postoperative management for non-small cell lung cancer harboring EGFR mutations. Journal of Thoracic Disease, 2020, 12, 4556-4560.	0.6	0
65	Novel malignant-mesothelioma-associated antigens (Gene-X and THBS-2) in the diagnosis of malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology, 2012, 30, 10585-10585.	0.8	0
66	Circulating tumor cell (CTC) as a significant clinical marker in epithelioid-type malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology, 2012, 30, 7080-7080.	0.8	0
67	Treatment strategy of EGFR-mutated non-small cell lung cancer. Journal of Thoracic Disease, 2022, 14, 602-606.	0.6	0